NEW YORK (GenomeWeb News) – Thomson Reuters today said that Cambridge, Mass.-based GenoSpace has joined its Life Sciences Partner Ecosystem and will work with the company to develop an integrated product offering for analyzing and interpreting human genomic variation.
Specifically, Thomson Reuters said that it will work with GenoSpace to annotate and publish a gene variant database, with an emphasis on medical and scientific utility. The platform will provide access to curated, medically relevant information, which will include pathway and disease biology as well as regulatory and financial information.
Joseph Donahue, senior vice president at Thomson Reuters, said the company expects through this partnership to provide "large-scale clinical genomic datasets and tools to help in annotating and interpreting genomic variation and support better informed medical treatment decisions." Customers will include hospitals, health systems, disease foundations, and pharmaceutical research organizations, he said.
GenoSpace CEO John Quackenbush added that by pairing his firm's ability to "synthesize" genomic and clinical data with the Thomson Reuters' information resources, "we are positioned to lead the implementation of personalized medicine."